drugset / Trial / NCT04242758

Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy

NCT04242758

Phase 4 Unknown 30 enrolled University of Pisa
RandomizedParallel-groupOpen-labelOther

Summary

In this open clinical trial, 30 subjects with inadequately controlled T2D and eligible, as per good clinical practice, for therapy with SGLT-2 inhibitor, will be randomized to receive a SGLT-2 inhibitor vs other oral-antidiabetic drugs (OADs) therapy for 3 months. Measures will be performed at baseline, after 2 days, after one month and at the end of the study protocol, as per good clinical practice

Timeline

Start
2019-06-04
Primary completion
2019-12-30
Completion
2020-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Hydrochlorothiazide Unknown 12.5 mg